CorMedix Inc.
CRMDDrugs in Pipeline
3
Phase 3 Programs
2
Upcoming Catalysts
1
Next Catalyst
Aug 13, 2026
10dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
CRMD Earnings Report
EPS Est: $0.26 | FQ end 2026-06 | Call: 2026-08-13 15:00:00
How CRMD's past catalysts played out
(taurolidine and heparin) catheter lock solution
Central Line Associated Blood Stream Infections (CLABSI)
Neutrolin
Kidney Failure, Chronic
CRMD-001-Deferiprone
Contrast-Induced Acute Kidney Injury
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
(taurolidine and heparin) catheter lock solution | Phase 3 | Central Line Associated Blood Stream Infections (CLABSI) | - | - |
Neutrolin | Phase 3 | Kidney Failure, Chronic | - | - |
CRMD-001-Deferiprone | Phase 2 | Contrast-Induced Acute Kidney Injury | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in CorMedix Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in CorMedix Inc.'s (CRMD) pipeline across Phase 3, Phase 2. Its lead program is (taurolidine and heparin) catheter lock solution (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is CorMedix Inc.'s next FDA catalyst?→
CorMedix Inc.'s (CRMD) next tracked catalyst is a Earnings expected August 13, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CRMD biotech catalysts?→
Add CRMD to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow CorMedix Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.